Kyoto University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kyoto University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014352
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kyoto University (Kyoto) is a research university that offers educational services. The university provides multi disciplinary courses to students of Japan including medicine, engineering, law, letters, and science. It offers medical services, and diagnoses and treats various health problems in the fields of psychiatry, dermatology, ophthalmology, internal medicine, otolaryngology, and sports orthopedic medicine. Kyoto conducts research programs on fetal brain development in chimpanzees, cerebral development in chimpanzees, and others. The university operates through faculties, graduate schools, research institutes, and research and educational centers. It operates in China, Indonesia, India, Thailand, Singapore, Malaysia, Peru, Ethiopia, Vietnam, the US, the UK, Zambia, Kenya, and other countries. Kyoto is headquartered in Kyoto, Japan.

Kyoto University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kyoto University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kyoto University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kyoto University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kyoto University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kyoto University, Medical Devices Deals, 2011 to YTD 2017 10
Kyoto University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Kyoto University, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
KinoPharma Raises USD1.3 Million in Financing Round 13
Kyoto University Innovation Capital to Invest in Kyoto drug discovery research institute 14
Stem Cell & Device Laboratory Raises USD1.8 Million in Series A Financing 15
Partnerships 16
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 16
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 17
Oncolys BioPharma Enters into Research Agreement with Kyoto University 18
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 19
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 20
CiRA Enters into Co-Development Agreement with Takeda Pharma 21
Shin Nippon Biomedical Labs Enters Into Research Agreement With Center For iPS Cells Research And Application 22
NanoCarrier Extends Research Agreement With Kyoto University 23
NanoCarrier Enters Into Research Agreement With Kyoto University 24
CiRA Enters Into Co-Development Agreement With Kyoto University And Dainippon Sumitomo 25
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 26
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 27
Licensing Agreements 28
FGH Biotech Enters into Licensing Agreement with Kyoto University and Tokyo University of Agriculture and Technology 28
Kyoto Drug Discovery & Development Enters into Licensing Agreement with Kyoto University 29
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 30
iPierian Enters Into Licensing Agreement With Kyoto University 31
Kyoto University And iPS Academia Enter Into Licensing Agreement With iPierian 32
Kyoto University – Key Competitors 33
Kyoto University – Key Employees 34
Kyoto University – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 37
Government and Public Interest 37
Jul 11, 2017: Accessing DNA in the cell’s powerhouse to treat disease 37
Jul 11, 2017: Killing cancer in the heat of the moment 38
Jun 05, 2017: Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments 39
Jun 03, 2016: Unusual combo reduces health risk from atypical antipsychotic 40
Product News 41
May 06, 2016: Researchers Report Progress as They Develop New Approach to Treating Metastatic Melanoma 41
Other Significant Developments 42
Jan 03, 2017: Japan’s foremost medical institute purchases multiple HoloMonitor instruments 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Kyoto University, Pharmaceuticals & Healthcare, Key Facts 2
Kyoto University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kyoto University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kyoto University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kyoto University, Deals By Therapy Area, 2011 to YTD 2017 9
Kyoto University, Medical Devices Deals, 2011 to YTD 2017 10
Kyoto University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
KinoPharma Raises USD1.3 Million in Financing Round 13
Kyoto University Innovation Capital to Invest in Kyoto drug discovery research institute 14
Stem Cell & Device Laboratory Raises USD1.8 Million in Series A Financing 15
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 16
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 17
Oncolys BioPharma Enters into Research Agreement with Kyoto University 18
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 19
Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 20
CiRA Enters into Co-Development Agreement with Takeda Pharma 21
Shin Nippon Biomedical Labs Enters Into Research Agreement With Center For iPS Cells Research And Application 22
NanoCarrier Extends Research Agreement With Kyoto University 23
NanoCarrier Enters Into Research Agreement With Kyoto University 24
CiRA Enters Into Co-Development Agreement With Kyoto University And Dainippon Sumitomo 25
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 26
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 27
FGH Biotech Enters into Licensing Agreement with Kyoto University and Tokyo University of Agriculture and Technology 28
Kyoto Drug Discovery & Development Enters into Licensing Agreement with Kyoto University 29
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 30
iPierian Enters Into Licensing Agreement With Kyoto University 31
Kyoto University And iPS Academia Enter Into Licensing Agreement With iPierian 32
Kyoto University, Key Competitors 33
Kyoto University, Key Employees 34
Kyoto University, Other Locations 35
Kyoto University, Subsidiaries 35

★海外企業調査レポート[Kyoto University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PCCW Limited:戦略・SWOT・企業財務分析
    PCCW Limited - Strategy, SWOT and Corporate Finance Report Summary PCCW Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dynasty Fine Wine Group Limited:企業の戦略・SWOT・財務分析
    Dynasty Fine Wine Group Limited - Strategy, SWOT and Corporate Finance Report Summary Dynasty Fine Wine Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Gradalis Inc-製薬・医療分野:企業M&A・提携分析
    Summary Gradalis Inc (Gradalis), formerly Murex Pharmaceuticals, is a biopharmaceutical company which focuses on the development and commercialization of therapies for the treatment of cancer. Its developmental pipeline comprises of candidates for various cancer indications which include ovarian, br …
  • Fugro GeoServices Ltd:企業の戦略的SWOT分析
    Fugro GeoServices Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Faroe Petroleum plc (FPM):企業の財務・戦略的SWOT分析
    Summary Faroe Petroleum Plc (Faroe Petroleum) is an oil and gas company that concentrates on exploration, appraisal, development and production opportunities. The company has its exploration and development assets in the UK. Its operations portfolio consists of exploration, appraisal, development an …
  • Beach Energy Ltd (BPT):石油・ガス:M&Aディール及び事業提携情報
    Summary Beach Energy Ltd (Beach Energy) is an independent upstream oil and gas company. It carries out the exploration, development, production, transportation and marketing of oil and natural gas. The company has core exploration and development drilling operations in the Cooper and Eromanga basins …
  • The Israel Electric Corporation Ltd-エネルギー分野:企業M&A・提携分析
    Summary The Israel Electric Corporation Ltd (IECL), formerly Palestine Electric Corporation Ltd. is an integrated electric utility that carries out the generation, transmission, distribution, sale and supply of electricity. The State of Israel owns around 99.85% of the company. It generates power ma …
  • Fraser & Neave Holdings Bhd:企業の戦略・SWOT・財務情報
    Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Fertin Pharma AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Fertin Pharma A/S (Fertin Pharma) is a pharmaceutical company that develops and manufactures medicated chewing gum. The company offers pharmaceutical chewing gum products for therapeutic areas such as allergy, cough and cold, nicotine replacement, gastrointestinal, pain and oral care, among …
  • Resilux NV:企業の戦略・SWOT・財務情報
    Resilux NV - Strategy, SWOT and Corporate Finance Report Summary Resilux NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Xencor Inc (XNCR):企業の財務・戦略的SWOT分析
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • OncoTherapy Science Inc (4564):医療機器:M&Aディール及び事業提携情報
    Summary OncoTherapy Science Inc (OncoTherapy) is a biotechnology company that discovers and develops antibody drugs for treating cancer. The company offers products under antibodies, cancer vaccines and small molecule drugs. It provides contract research services. OncoTherapy conducts research and d …
  • Virginia Electric and Power Company:企業の発電所・SWOT分析2018
    Virginia Electric and Power Company - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • First Light Biosciences Inc:製品パイプライン分析
    Summary First Light Biosciences Inc (FLB) is a medical device company that develops and manufactures automated medical diagnostic products for detection of healthcare associated infections. The company’s product include multipath analyzer. Its multipath analyzer detects resistant and sensitive staph …
  • BDO International Limited:戦略・SWOT・企業財務分析
    BDO International Limited - Strategy, SWOT and Corporate Finance Report Summary BDO International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Century Enka Limited:企業の戦略・SWOT・財務分析
    Century Enka Limited - Strategy, SWOT and Corporate Finance Report Summary Century Enka Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Galp Energia SGPS SA (GALP)-石油・ガス分野:企業M&A・提携分析
    Summary Galp Energia SGPS S.A. (Galp Energia) is an integrated oil and natural gas company. It explores for, develops and produces crude oil and natural gas; refines crude oil and markets refined petroleum products. The company also imports, transports and distributes natural gas. It conducts the na …
  • Hitachi Kokusai Electronic Inc.:企業の戦略・SWOT・財務情報
    Hitachi Kokusai Electronic Inc. - Strategy, SWOT and Corporate Finance Report Summary Hitachi Kokusai Electronic Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Providence Resources plc (PZQA):企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …
  • Humana Inc (HUM)-製薬・医療分野:企業M&A・提携分析
    Summary Humana Inc (Humana) is a health and well-being company that offers health insurance and Medicare plans, insurance products, and health and wellness services to healthcare providers, employers, individuals, administrators, government, and the public sector. The company’s Medicare products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆